EA200800642A1 - SPECIFIC TO SA6 ANTIGEN CYTOTOXIC CONJUGATE AND METHODS OF ITS APPLICATION - Google Patents

SPECIFIC TO SA6 ANTIGEN CYTOTOXIC CONJUGATE AND METHODS OF ITS APPLICATION

Info

Publication number
EA200800642A1
EA200800642A1 EA200800642A EA200800642A EA200800642A1 EA 200800642 A1 EA200800642 A1 EA 200800642A1 EA 200800642 A EA200800642 A EA 200800642A EA 200800642 A EA200800642 A EA 200800642A EA 200800642 A1 EA200800642 A1 EA 200800642A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
specific
application
cytotoxic
conjugate
Prior art date
Application number
EA200800642A
Other languages
Russian (ru)
Other versions
EA020130B1 (en
EA020130B9 (en
Inventor
Джиллиан Пайн
Филип Чан
Дэниэл Таварес
Original Assignee
Иммьюноджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иммьюноджен, Инк. filed Critical Иммьюноджен, Инк.
Publication of EA200800642A1 publication Critical patent/EA200800642A1/en
Publication of EA020130B1 publication Critical patent/EA020130B1/en
Publication of EA020130B9 publication Critical patent/EA020130B9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Представлены цитотоксические конъюгаты, включающие агента, связывающего клетку, и цитотоксического агента, терапевтические композиции, включающие конъюгат, способы применения этих конъюгатов при ингибировании роста клеток и лечении заболеваний, и набор, включающий цитотоксический конъюгат, которые составляют все воплощения изобретения. В частности, агентом, связывающим клетку, является моноклональное антитело и его эпитоп-связывающие фрагменты, которые распознают и связываются с гликотопом СА6. Настоящее изобретение также направлено на гуманизованные или перестроенные варианты моноклонального антитела DS6 мыши против СА6 и его эпитоп-связывающие фрагменты.Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions including a conjugate, methods of using these conjugates in inhibiting cell growth and treating diseases, and a kit comprising a cytotoxic conjugate that comprise all embodiments of the invention are presented. In particular, the cell binding agent is a monoclonal antibody and its epitope-binding fragments that recognize and bind to the CA6 glycotope. The present invention is also directed to humanized or rearranged versions of a mouse DS6 monoclonal antibody against CA6 and its epitope-binding fragments.

EA200800642A 2005-08-22 2005-08-22 A ca6 antigen-specific antibody, cytotoxic conjugate comprising same and methods of using conjugate EA020130B9 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/030115 WO2007024222A1 (en) 2005-08-22 2005-08-22 A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Publications (3)

Publication Number Publication Date
EA200800642A1 true EA200800642A1 (en) 2008-08-29
EA020130B1 EA020130B1 (en) 2014-08-29
EA020130B9 EA020130B9 (en) 2014-10-30

Family

ID=37771883

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800642A EA020130B9 (en) 2005-08-22 2005-08-22 A ca6 antigen-specific antibody, cytotoxic conjugate comprising same and methods of using conjugate

Country Status (13)

Country Link
EP (1) EP1917034A4 (en)
JP (1) JP2009504193A (en)
CN (1) CN101242855A (en)
AU (1) AU2005335743A1 (en)
BR (1) BRPI0520509A2 (en)
CA (1) CA2615761A1 (en)
EA (1) EA020130B9 (en)
EC (1) ECSP088241A (en)
HK (1) HK1211965A1 (en)
IL (2) IL189628A0 (en)
MX (1) MX2008002607A (en)
NO (1) NO20080893L (en)
WO (1) WO2007024222A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
RU2015137856A (en) * 2013-02-05 2017-03-13 Санофи IMMUNOLOGICAL VISUALIZING AGENT FOR USE IN ANTI-MEDICINE CONJUGATE TREATMENT
CA2900154A1 (en) * 2013-02-05 2014-08-14 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9844607B2 (en) 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
US9989524B2 (en) 2013-02-05 2018-06-05 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
JP2016525560A (en) * 2013-08-02 2016-08-25 サノフイ Use of anti-Muc1 maytansinoid immunoconjugate antibodies to treat solid tumors
WO2016036861A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
TWI697493B (en) 2014-09-03 2020-07-01 美商免疫原公司 Cytotoxic benzodiazepine derivatives
RS65120B1 (en) 2015-11-25 2024-02-29 Immunogen Inc Pharmaceutical formulations and methods of use thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
CN116785450A (en) 2017-02-28 2023-09-22 伊缪诺金公司 Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof
TW201839001A (en) 2017-04-20 2018-11-01 美商伊繆諾金公司 Cytotoxic benzodiazepine derivatives and conjugates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
CN102940889A (en) * 2003-05-14 2013-02-27 伊缪诺金公司 Drug conjugate composition
WO2005009369A2 (en) * 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same

Also Published As

Publication number Publication date
CN101242855A (en) 2008-08-13
EP1917034A1 (en) 2008-05-07
JP2009504193A (en) 2009-02-05
ECSP088241A (en) 2008-04-28
HK1211965A1 (en) 2016-06-03
EA020130B1 (en) 2014-08-29
IL238798A0 (en) 2015-06-30
AU2005335743A1 (en) 2007-03-01
WO2007024222A1 (en) 2007-03-01
MX2008002607A (en) 2008-03-19
IL189628A0 (en) 2008-06-05
EP1917034A4 (en) 2009-04-29
CA2615761A1 (en) 2007-03-01
BRPI0520509A2 (en) 2009-05-12
NO20080893L (en) 2008-05-22
EA020130B9 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
EA200800642A1 (en) SPECIFIC TO SA6 ANTIGEN CYTOTOXIC CONJUGATE AND METHODS OF ITS APPLICATION
EA200600275A1 (en) CYTOTOXIC CONJUGAT, SPECIFICALLY RELATED TO CA6 ANTIGEN, AND METHODS OF ITS APPLICATION
EA200800952A1 (en) CONJUGATES ANTIBODY-DRUG AND METHODS OF APPLICATION
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
EA200702053A1 (en) ANTIBODIES AGAINST CD38 FOR THE TREATMENT OF MULTIPLE MYELOMA
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
MXPA06003788A (en) Fully human antibodies against human 4-1bb (cd137).
EA200801930A1 (en) BISPECIFIC MOLECULE, BINDING TLR9 AND CD32 AND CONTAINING T-CELL EPITOPE FOR THE TREATMENT OF ALLERGIES
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2005103081A3 (en) Human monoclonal antibodies against cd20
GEP20135826B (en) Novel antibodies used to treat cancer
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
DK1730196T3 (en) EphB4-binding antibodies to inhibit antiogenesis and tumor growth
CR9823A (en) AN ANTIGEN-SPECIFIC CA6 CYTOTOXIC CONJUGATE AND METHODS TO USE THE SAME
EA202190387A1 (en) ANTIBODY TO HUMAN CD38 AND ITS USE

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM